Literature DB >> 28943178

Factors associated with degree of tumour response to neo-adjuvant radiotherapy in rectal cancer and subsequent corresponding outcomes.

K J Gash1, O Baser2, R P Kiran3.   

Abstract

BACKGROUND: Tumour response to neo-adjuvant radiotherapy for rectal cancer varies significantly between patients, as classified by Tumour Regression Grade (TRG 0-3), with 0 equating to pathological complete response (pCR) and 3 denoting minimal/no response. pCR is associated with significantly better local recurrence rates and survival, but is achieved in only 20-30% of patients. The literature contains limited data reporting factors predictive of tumour response and corresponding outcomes according to degree of regression.
METHODS: All patients with rectal cancer who received neo-adjuvant radiotherapy, entered into the National Cancer Database (NCDB) in 2009-2013, were included. Data were analysed on procedure performed, tumour details, pathological findings, chemo-radiotherapy regimens, patient demographics, outcomes and survival. Multivariate regression analysis was used to identify factors independently associated with pCR.
RESULTS: Of 13,742 patients, 32.4% achieved pCR/TRG0 (4452). Factors associated with pCR (vs. TRG3) included adenocarcinoma rather than mucinous adenocarcinoma histology; well/moderately differentiated grade; lower clinical tumour (cT1, cT2, cT3) and nodal (N0 and N1) stage, and the addition of neo-adjuvant chemotherapy. Elevated CEA levels were associated with TRG3. pCR patients had higher rates of local excision, shorter mean length of stay and lower unplanned readmission rates, than TRG3. R0 resection rates and overall survival were significantly higher in all grades of regression, compared to TRG3 (p < 0.0001).
CONCLUSION: Tumour regression correlates with outcomes. Identifying factors predictive of response may facilitate higher pCR rates, the tailoring of therapy, and improve outcomes.
Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Neo-adjuvant radiotherapy; Pathological complete response; Rectal cancer; Regression grade; Tumour response

Mesh:

Year:  2017        PMID: 28943178     DOI: 10.1016/j.ejso.2017.07.024

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  The potential benefit of adjuvant chemotherapy in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy is not predicted by tumor regression grade.

Authors:  Ali Bohlok; Alain Hendlisz; Fikri Bouazza; Maria Gomez Galdon; Jean Van de Stadt; Luigi Moretti; Issam El Nakadi; Gabriel Liberale
Journal:  Int J Colorectal Dis       Date:  2018-07-08       Impact factor: 2.571

2.  Clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment.

Authors:  Weerapat Suwanthanma; Saowanee Kitudomrat; Chakrapan Euanorasetr
Journal:  Medicine (Baltimore)       Date:  2021-09-24       Impact factor: 1.817

3.  Do microsatellite instability (MSI) and deficient mismatch repair (dMMR) affect the pathologic complete response (pCR) in patients with rectal cancer who received neoadjuvant treatment?

Authors:  Turan Acar; Nihan Acar; Erdinç Kamer; Mustafa Agah Tekindal; Fevzi Cengiz; Haldun Kar; Kemal Atahan; Mehmet Haciyanli
Journal:  Updates Surg       Date:  2019-12-20

4.  MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer.

Authors:  Maxiaowei Song; Shuai Li; Hongzhi Wang; Ke Hu; Fengwei Wang; Huajing Teng; Zhi Wang; Jin Liu; Angela Y Jia; Yong Cai; Yongheng Li; Xianggao Zhu; Jianhao Geng; Yangzi Zhang; XiangBo Wan; Weihu Wang
Journal:  Br J Cancer       Date:  2022-04-02       Impact factor: 9.075

5.  Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Colorectal Carcinoma: A Potential Area of Focus for Future Diagnostics.

Authors:  Simrandeep Kaur; Karamjit S Gill; Mridu Manjari; Surinder Kumar; Shreya Nauhria; Reetuparna Nath; Chandni Patel; Kamal Hamdan; Yujin Jeong; Narendra P Nayak; Sabyasachi Maity; Rob Hilgers; Samal Nauhria
Journal:  Cureus       Date:  2022-03-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.